Bleeding ,Arrhythmias, Heart Failure, Acute Renal Failure, Acute Liver Failure, Dyspnoea, Gout
Conditions
Keywords
Acute coronary syndrome, thienopyridine, epidemiology
Brief summary
The purpose of the study is to describe patient characteristics and drug usage among patients that are prescribed ticagrelor for the first time and to compare them with patients who are prescribed clopidogrel and prasugrel for the first time. A further purpose is to ascertain and estimate the crude incidence rate of bleeding, arrhythmias, heart failure, acute renal failure, acute liver failure, dyspnoea and gout among new users in the three cohorts of ticagrelor, clopidogrel and prasugrel.
Interventions
DRUGRisk of selected safety events
First time users of ticagrelor, clopidogrel and prasugrel, respectively
Sponsors
AstraZeneca
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* First time users of ticagrelor, clopidogrel and prasugrel, respectively
Exclusion criteria
* Individuals with more than one of above three antiplatelet drugs dispensed the same day
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Drug utilization: Description of patient characteristics and drug usage | Up to one year after entry into study cohort |
Secondary
| Measure | Time frame |
|---|---|
| Follow-up of safety outcomes: First occurrence of bleeding, arrhythmias, heart failure, acute renal failure, acute liver failure, dyspnoea and gout | Up to one year after entry into study cohort. |
Countries
Sweden
Outcome results
None listed